Cindy Atwell
Chief Development Officer
Cindy Atwell is the Chief Development Officer overseeing development for the Company’s clinical programs. Cindy joined Precision BioSciences in 2019 and served as its Chief Business Officer prior to her promotion to Chief Development Officer.
Under Cindy’s leadership, Precision advanced multiple in vivo gene editing programs through regulatory milestones including IND clearance in the US, and CTA clearance in the European Union, United Kingdom, New Zealand, and Hong Kong enabling rapid movement of programs to the clinic.
Cindy has over twenty years of multi-disciplinary experience in the biopharma industry including various roles at Halozyme, AbbVie, Amylin, Impax, and start-up biotech companies. Over the course of her career, she has led or participated in the negotiation of a number of transactions, totaling >$10Bn in value. This includes the Novartis-Precision sickle cell gene editing strategic collaboration.
Cindy holds a BS in biochemistry and molecular biology from the Pennsylvania State University and an MBA from the University of California, San Diego’s Rady School of Management.